1
|
Bartoli-Leonard F, Rogers M, Zheng K, Small A, Asano T, Kuraoka S, Blaser M, Natarajan P, Yeang C, Tsimikas S, O'donnell C, Aikawa M, Singh S, Stroes E, Aikawa E. Inhibition of novel lipoprotein(a) receptor major facilitator superfamily domain containing 5 (MFSD5) reduces development of aortic valve calcification. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Other. Main funding source(s): Private grant from Kowa Pharmaceuticals to Brigham and Woman's Hospital
Calcific aortic valve stenosis (CAVS) is the most prevent valvular heart disease in the western world increasing exponentially with age, with an 112% increase in CAVS deaths in the last three decades; however no therapeutic treatment is currently available. Recently, lipoprotein(a) [Lp(a)] has been demonstrated to be an independent and causal risk factor for CAVS, yet the understanding of its cellular uptake and catabolism is limited thus underscoring the need for further investigation.
This study aimed to determine a target receptor, unique for Lp(a) on the surface of valvular interstitial cells (VICs) and ascertain the role of the receptor on the development of VIC calcification.
Unbiased ligand-receptor capture mass spectrometry (TriCEPS) was used to identify target receptor, with western blotting, ELISA, qPCR, alizarin red calcium staining and immunofluorescence used to validate the targets in vitro via siRNA inhibition and overexpression. Transmission electron microscopy (TEM) was used to determine uptake of Lp(a) within excised human valves. Identification of small molecule inhibitors was assessed computationally via the L1000 dataset, with the top hit candidate validated in vitro. Genotype-phenotype studies were examined using the United Kingdom Biobank (UKBB) and the Millions Veterans Program. Linear regression was used to evaluate association between aortic stenosis and plasma Lp(a) levels, and a phenotype-wide association analysis was then performed against this generated ‘genotype’.
Ligand-receptor capture mass spectrometry was used to detect novel membrane proteins with specific binding to Lp(a); MFSD5, MRC2, LDLR were identified as possible candidates. MFSD5 RNAscope demonstrated its presence in human aortic valves. Lp(a) uptake in VICs was confirmed via western blot and TEM. MFSD5 siRNA significantly reduced dil-labelled Lp(a) uptake in human VICs (p=0.003) and HEPG2 cells (p=0.0003), conversely MFSD5 overexpression increased uptake (p=0.0345, p=0.0318), whilst specificity of MFSD5 to Lp(a) alone was shown via no change in LDL uptake following MFSD5 inhibition (p=0.616, p=0.991). MFSD5 inhibition reduced RUNX2 (p=0.0124) and Osteocalcin (p<0.001) RNA expression and reduced alizarin red staining following culture in Lp(a) osteogenic media for 21 days (p<0.0033). Druggability of MFSD5 was confirmed by the L1000 database, which identified aminopurvalanol as a binding partner for MFSD5 and significantly reduced Lp(a) uptake within VICs (p=0.0091). MFSD5-loss of function within the UKBB showed no significant cardiovascular association, however 50kb +/- of the MFSD5 gene showed nominal association with hyperlipidaemia and atrial fibrillation.
The current study demonstrates the novel Lp(a) receptor MFSD5 may be responsible for uptake of Lp(a) within VICs, resulting in the development of aortic valve calcification, highlighting the need for further exploration into the role of MFSD5 in aortic valve disease.
Collapse
Affiliation(s)
- F Bartoli-Leonard
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - M Rogers
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - K Zheng
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - A Small
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - T Asano
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - S Kuraoka
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - M Blaser
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - P Natarajan
- Boston VA Healthcare System , Boston , United States of America
| | - C Yeang
- University of California, San Diego , San Diego , United States of America
| | - S Tsimikas
- University of California, San Diego , San Diego , United States of America
| | - C O'donnell
- Boston VA Healthcare System , Boston , United States of America
| | - M Aikawa
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - S Singh
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - E Stroes
- Amsterdam UMC - Location Academic Medical Center , Amsterdam , Netherlands (The)
| | - E Aikawa
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| |
Collapse
|
2
|
Yeang C, Su F, Witztum J, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Boffa M, Marar T, Borrelli M, Yeang C, Viney N, Xia S, Witztum J, Koschinsky M, Tsimikas S. Reduction Of Plasma Lipoprotein(A) With Antisense Oligonucleotides In Human Subjects Does Not Affect Fibrinolysis. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
4
|
Yeang C, Miu P, Green S, Yang X, Hung M, Witztum J, Tsimikas S. Defining the mechanism of lipoprotein(a) [Lp(a)] lowering by alirocumab in transgenic mouse models. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Yeang C, Tsimikas S. Lipoprotein(a)-cholesterol (Lp(a)-C) levels determined by vertical auto profile (VAP) correlates weakly with Lp(a) mass but modestly with HDL-C: Implications for appropriate interpretation of clinical data. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
6
|
Yeang C, Hung M, Pattison J, Bowden K, Dalton N, Peterson K, Witztum J, Tsimikas S, Que X. Expression of E06, a natural monoclonal antibody targeted to oxidized phospholipids (OXPL), attenuates the progression of aortic sclerosis in aged hyperlipidemic mice. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|